Aim: To investigate whether risk of relapse of endometrial hyperplasia persists many years after successful primary therapy and whether clinical or biological markers observed at primary diagnosis may predict relapse.
Materials And Methods: A series of 57 women with endometrial hyperplasia received levonorgestrel-impregnated intrauterine system or oral progestin for three months during 1998-2000. Index biopsies were classified according to WHO1994 and D-score systems, and immunohistochemical staining for estrogen receptor α (ERα), estrogen receptor β (ERβ), progesterone receptor A (PRA), progesterone receptor B (PRB), B-cell lymphoma 2/apoptosis regulator (BCL2), BCL2-associated X protein/apoptosis regulator (BAX), paired box 2 (PAX2), and phosphatase and tensin homolog (PTEN) reported as H-scores.
Results: Over a follow-up of 157.8 months, 23% (10/43) of patients experienced relapse. No correlation with age, body mass index, parity, WHO94 classification, or D-score was found. Only PRA (p=0.004) and PRB (p=0.038) showed certain correlation with relapse.
Conclusion: Endometrial hyperplasia recurs many years after successful progestin therapy. Increased expression of PRB and reduced expression of PRA significantly correlated with relapse. Our results support the importance of continuous endometrial protection and the need for new clinical surveillance guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.21873/anticanres.11595 | DOI Listing |
Georgian Med News
October 2024
Azerbaijan Medical University, Department of Obstetrics and Gynecology II, Baku, Azerbaijan.
The Aim Of The Study: to examine the pathomorphological and clinical characteristics of the uterus in the combined form of fibroids and adenomyosis.
Methods: The research work was conducted within the framework of the scientific program of the Department of Obstetrics and Gynecology II at Azerbaijan Medical University for the years 2021-2024. In the course of this study, a comprehensive clinical, laboratory, and instrumental prospective examination was conducted on 113 patients aged 30 to 50 years (mean age 42,0±1,8 years) with combined adenomyosis and uterine fibroids.
Int J Surg Case Rep
December 2024
Clinica Universitaria Reina Fabiola, Córdoba, Argentina.
Introduction: Appendiceal endometriosis (AE) is a rare condition, with a prevalence ranging from 0.05 % to 1.7 % in patients with endometriosis.
View Article and Find Full Text PDFWiad Lek
December 2024
UNIVERSITY OF PRESOV, PRESOV, SLOVAK REPUBLIC.
Objective: Aim: Investigation of hyperproliferative diseases of the female genital organs as a consequence of mixed urogenital infections.
Patients And Methods: Materials and Methods: The study included 56 women of reproductive age who experienced discomfort in the external genital area in the form of excessive vaginal discharge and/or unpleasant odour of the discharge, itching in the external genital area (main group). The control group consisted of 30 somatically and gynaecologically healthy patients.
Int J Womens Health
November 2024
Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.
Aim: To assess body composition, glucolipid metabolism, and uric acid levels in PCOS (Polycystic Ovary Syndrome) patients to determine their relationship with the risk of endometrial hyperplasia (EH).
Methods: A total of 232 patients were included and divided into groups according to whether they had PCOS and endometrial pathology (Group A: non-PCOS and normal endometrium; Group B: PCOS and normal endometrium; Group C: non-PCOS and EH; Group D: PCOS and EH). Body composition differences between groups and correlations between body composition, glucolipid metabolism, and uric acid levels were analyzed.
Theriogenology
November 2024
Dipartimento di Scienze Veterinarie, Università di Pisa, Via Livornese (Lato Monte), 1289, San Piero a Grado, PI, Pisa, 56122, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!